Get started

MediLink Therapeutics (Suzhou) Co., Ltd. (China)

Alternate names: MediLink Therapeutics, MediLink Therapeutics (Suzhou), MediLink Therapeutics (Suzhou) Co., Ltd., Suzhou Medilink Therapeutics Ltd.
ROR: 03tfhs542
OpenAlex ID: I4405267671
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
2025 · Yuxiang Ma, Yunpeng Yang, et al. · Nature Medicine · 135
YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial.
2024 · Ying Cheng, Xiaochen Zhang, et al. · Journal of Clinical Oncology · 10
241P Development and characterization of a novel DLL3-targeting antibody drug conjugate (ADC) for the treatment of solid tumors
2024 · L.N. Lin, B. Wan, et al. · ESMO Open · 8
605O YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
2024 · H. Zhao, Y. Ma, et al. · Annals of Oncology · 7
Abstract 596: Development and assessment of a novel tumor microenvironment activable linker (TMALIN) ADC platform for solid tumor treatments
2023 · Jiaqiang Cai, Shuai Song, et al. · Cancer Research · 6
Abstract 1804: An innovative dual-payload ADC combining topoisomerase 1 inhibitor and a tubulin inhibitor efficiently overcomes drug resistance
2025 · Ailin Shan, Chun Deng, et al. · Cancer Research · 5
Abstract 3140: Preclinical development of YL242, a non-internalized antibody-drug conjugate (ADC) targeting soluble VEGF for treatment of solid tumors
2025 · Tongtong Xue, Wei Lian, et al. · Cancer Research · 5
Abstract 2940: Preclinical development of a next generation antibody drug conjugate (ADC) targeting CDH17 for treatment of solid tumors
2025 · Wei Lian, Qing Zong, et al. · Cancer Research · 5
Abstract 4702: MediLink’s TMALIN ADC linker technology: Tumor microenvironment specific extracellular and intracellular double cleavage mechanism for better efficacy and expanded target space
2024 · Tongtong Xue, Liang Xiao, et al. · Cancer Research · 5
Abstract 1894: Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker-payload for treatment of solid tumors
2024 · Liang Xiao, Wei Lian, et al. · Cancer Research · 5
Abstract 6304: Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors
2023 · Jian Xu, Qing Zong, et al. · Cancer Research · 5
329P: Intracranial efficacy of YL201, a novel B7-H3-targeting antibody-drug conjugate (ADC), in patients (pts) with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)
2025 · H. Zhao, Y. Ma, et al. · Journal of Thoracic Oncology · 4
PDF
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
2026 · Yuanyuan Zhao, Hongxu Liu, et al. · New England Journal of Medicine · 3
YL205, a novel anti-Napi2b antibody drug conjugate (ADC), in patients with ovarian cancer: Preliminary result from a first-in-human trial.
2026 · Xiaohua Wu, Haifeng Liu, et al. · Journal of Clinical Oncology · 3
Abstract 563: Preclinical development of YL202, a novel HER3-targeting antibody-drug conjugate (ADC) with novel DNA topoisomerase I inhibitor for treatment of solid tumors
2023 · Jian Xu, Qing Zong, et al. · Cancer Research · 3
Phase 1/2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in patients with relapsed or refractory (R/R) Ewing sarcoma and chondrosarcoma.
2026 · Lu Xie, Jie Zang, et al. · Journal of Clinical Oncology · 2
Phase 1/2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in patients with previously treated advanced pancreatic ductal adenocarcinoma (PDAC).
2026 · Liwei Wang, Yanqiao Zhang, et al. · Journal of Clinical Oncology · 1
Phase 2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
2026 · Dingwei Ye, Zhisong He, et al. · Journal of Clinical Oncology · 1
11MO First disclosure of efficacy and safety data for YL202/BNT326 (HER3 ADC) from a phase II trial in patients (pts) with non-small cell lung cancer (NSCLC)
2026 · H. Liu, Z. Huang, et al. · ESMO Open · 1
PDF
Abstract 2615: Preclinical development of a next generation antibody drug conjugate (ADC) targeting cMET for treatment of solid tumors
2024 · Liang Xiao, Wei Lian, et al. · Cancer Research · 1
MO15.04: First-Line YL201 Plus Serplulimab in ES-SCLC and Advanced NSCLC: Phase 1 Results of a B7-H3-Directed Combination Strategy
2026 · H. Zhao, L. Wu, et al. · Journal of Thoracic Oncology
PL02.03: Tam-Peli, an Anti-B7-H3 Antibody-Drug Conjugate, Versus Topotecan in Relapsed SCLC: A Randomized, Open-Label, Phase 3 Study
2026 · L. Zhang, Y. Zhao, et al. · Journal of Thoracic Oncology
One step conversion of tert-butyl ester to corresponding acyl chloride by thionyl chloride using water-free acetonitrile as solvent
2026 · Shuai Song, Tongtong Xue, et al. · Tetrahedron Letters
Abstract 5655: YL252: A dual-functional PD-L1/VEGF-targeting ADC integrating immunotherapy, anti-angiogenesis, and cytotoxicity.
2026 · Wei Lian, Xinzhen Shi, et al. · Cancer Research
Abstract 1765: YL413: A novel dual-payload anti-HER2 antibody-drug conjugate demonstrating potent preclinical activity
2026 · Hanwen Deng, Tao Wang, et al. · Cancer Research
Works count: 26
Citation count: 1,034
Year
Topic
Type